Pharmaceutical Capsules #3150775

We are engaged in the business of exporting highly effective Pharmaceutical Capsules, which are procured from the most reliable sources. Prepared using the accurate combination of different chemicals, these Pharmaceutical Capsules are widely recommended by renowned medical practitioners. These Pharmaceutical Capsules are widely used for the treatment of various ailments so as to provide relief to the patients.
Pharmaceutical Capsules are widely used for medical purpose in the pharmaceutical industry. Various Pharmaceutical Capsules, offered by us, are mentioned below:

Cristaclor 250 capsules :

• Cefaclor
• USP 250 mg

Cristaclor 500 capsules :

• Cefaclor
• USP 500 mg

Zozibact 250 capsules :

• Azithromycin
• USP 250 mg

TEMODAR contains temozolomide, an imidazotetrazine derivative. The chemical name of temozolomide is 3, 4-dihydro-3methyl-4-oxoimidazo[5, 1-d]-as-tetrazine-8-carboxamide. The structural formula is:
TEMODAR® (temozolomide) Structural Formula IllustrationThe material is a white to light tan/light pink powder with a molecular formula of C 6H6N6O2 and a molecular weight of 194.15. The molecule is stable at acidic pH ( < 5) and labile at pH > 7; hence TEMODAR can be administered orally and intravenously. The prodrug, temozolomide, is rapidly hydrolyzed to the active 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC) at neutral and alkaline pH values, with hydrolysis taking place even faster at alkaline pH.

TEMODAR Capsules : Each capsule for oral use contains either 5 mg, 20 mg, 100 mg, 140 mg, 180 mg, or 250 mg of temozolomide.

The inactive ingredients for TEMODAR Capsules are as follows :

• TEMODAR 5 mg : lactose anhydrous (132.8 mg), colloidal silicon dioxide (0.2 mg), sodium starch glycolate (7.5 mg), tartaric acid (1.5 mg), and stearic acid (3 mg).
• TEMODAR 20 mg : lactose anhydrous (182.2 mg), colloidal silicon dioxide (0.2 mg), sodium starch glycolate (11 mg), tartaric acid (2.2 mg), and stearic acid (4.4 mg).
• TEMODAR 100 mg : lactose anhydrous (175.7 mg), colloidal silicon dioxide (0.3 mg), sodium starch glycolate (15 mg), tartaric acid (3 mg), and stearic acid (6 mg).
• TEMODAR 140 mg : lactose anhydrous (246 mg), colloidal silicon dioxide (0.4 mg), sodium starch glycolate (21 mg), tartaric acid (4.2 mg), and stearic acid (8.4 mg).
• TEMODAR 180 mg : lactose anhydrous (316.3 mg), colloidal silicon dioxide (0.5 mg), sodium starch glycolate (27 mg), tartaric acid (5.4 mg), and stearic acid (10.8 mg).
• TEMODAR 250 mg : lactose anhydrous (154.3 mg), colloidal silicon dioxide (0.7 mg), sodium starch glycolate (22.5 mg), tartaric acid (9 mg), and stearic acid (13.5 mg).

The body of the capsules is made of gelatin, and is opaque white. The cap is also made of gelatin, and the colors vary based on the dosage strength. The capsule body and cap are imprinted with pharmaceutical branding ink, which contains shellac, dehydrated alcohol, isopropyl alcohol, butyl alcohol, propylene glycol, purified water, strong ammonia solution, potassium hydroxide, and ferric oxide.

• TEMODAR 5 mg : The green cap contains gelatin, titanium dioxide, iron oxide yellow, sodium lauryl sulfate, and FD&C Blue #2.
• TEMODAR 20 mg : The yellow cap contains gelatin, sodium lauryl sulfate, and iron oxide yellow.
• TEMODAR 100 mg : The pink cap contains gelatin, titanium dioxide, sodium lauryl sulfate, and iron oxide red.
• TEMODAR 140 mg : The blue cap contains gelatin, sodium lauryl sulfate, and FD&C Blue #2.
• TEMODAR 180 mg : The orange cap contains gelatin, iron oxide red, iron oxide yellow, titanium dioxide, and sodium lauryl sulfate.
• TEMODAR 250 mg : The white cap contains gelatin, titanium dioxide, and sodium lauryl sulfate.

TEMODAR for Injection : Each vial contains 100 mg of sterile and pyrogen-free temozolomide lyophilized powder for intravenous injection.
The inactive ingredients are : Mannitol (600 mg), L-threonine (160 mg), polysorbate 80 (120 mg), sodium citrate dihydrate (235 mg) and hydrochloric acid (160 mg).

REVLIMID, a thalidomide analogue, is an immunomodulatory agent with antiangiogenic and antineoplastic properties. The chemical name is 3(4-amino-1-oxo 1, 3-dihydro-2H-isoindol-2-yl) piperidine-2, 6-dione and it has the following chemical structure:
REVLIMID [lenalidomide] Structural Formula Illustration
3-(4-amino-1-oxo 1, 3-dihydro-2H-isoindol-2-yl) piperidine-2, 6-dione
The empirical formula for lenalidomide is C13H13N3O3, and the gram molecular weight is 259.3.
Lenalidomide is an off-white to pale-yellow solid powder. It is soluble in organic solvent/water mixtures, and buffered aqueous solvents. Lenalidomide is more soluble in organic solvents and low pH solutions. Solubility was significantly lower in less acidic buffers, ranging from about 0.4 to 0.5 mg/ml. Lenalidomide has an asymmetric carbon atom and can exist as the optically active forms S(-) and R(+), and is produced as a racemic mixture with a net optical rotation of zero.
REVLIMID is available in 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration. Each capsule contains lenalidomide as the active ingredient and the following inactive ingredients: lactose anhydrous, microcrystalline cellulose, croscarmellose sodium, and magnesium stearate. The 5 mg and 25 mg capsule shell contains gelatin, titanium dioxide and black ink. The 2.5 mg and 10 mg capsule shell contains gelatin, FD&C blue #2, yellow iron oxide, titanium dioxide and black ink. The 15 mg capsule shell contains gelatin, FD&C blue #2, titanium dioxide and black ink. The 20 mg capsule shell contains gelatin, FD&C blue #2, yellow iron oxide, titanium dioxide and black ink.

HYDREA® (hydroxyurea capsules, USP) is an antineoplastic agent available for oral use as capsules providing 500 mg hydroxyurea. Inactive ingredients: citric acid, colorants (D&C Yellow No. 10, FD&C Blue No. 1, FD&C Red 40, and D&C Red 28), gelatin, lactose, magnesium stearate, sodium phosphate, and titanium dioxide.
Hydroxyurea is an essentially tasteless, white crystalline powder. Its structural formula is:
HYDREA® (hydroxyurea) Structural Formula Illustration